06 — Mainstream Longevity / Quantified-Self (the "wellness/optimization" wing)

Scene map + link-out. Last updated 2026-05-31.

This is the commercially dominant, normie-facing wing of biohacking: podcast-driven self-optimization, supplement stacks, wearables, and "longevity medicine" for the affluent. It is the part of the map your grandmother has heard of. It is also the part with the most marketing, the most grift, and the loosest relationship between claims and evidence.

Scope note. The actual science (interventions, evidence tiers, theories of aging, funding) is already covered in depth in /workspace/health/longevity/ and /workspace/health/peptides/. This doc does not redo that. Its job is to map the people, culture, and commerce of the optimization scene and place it on the overall biohacking map. For "does X work?", follow the cross-links — do not trust the influencers in this doc as primary sources.

TL;DR

• This wing is lifestyle optimization + consumer longevity medicine, not hard transhumanism. Its core practices (exercise, sleep, metabolic health) have the strongest evidence of anything in biohacking; its branding (supplements, gadgets, $2M/yr protocols, biological-age "scores") is where the hype lives.
• Flagship figures: Bryan Johnson (Blueprint / "Don't Die"), Andrew Huberman (Huberman Lab), Peter Attia (Outlive / "Medicine 3.0"), Dave Asprey (Bulletproof, popularized "biohacking"), Ben Greenfield. Each runs a media → audience → commerce funnel; several have credibility scandals.
• Intervention canon: exercise/VO2max, sleep, rapamycin, metformin, NAD+/NMN, senolytics, TRT/HRT, GLP-1s (Ozempic as the breakout longevity-crossover drug), peptides (→ peptides folder), sauna/cold, CGMs + wearables (Oura, Whoop, Levels). Evidence ranges from rock-solid (exercise) to debunked (resveratrol) to early/speculative (most supplements, senolytics).
• Commerce is the point: vendor estimates for the broad "biohacking" market scatter widely — roughly ~$20B–$45B for 2025 across firms (GMInsights ~$28.2B; Astute Analytica ~$38B; others $20–45B), with 10-year forecasts running ~$110B–$217B. Treat these as squishy directional figures, not precise truth (C4). Either way it's an "optimization" economy of supplements, rings, blood panels, and clinics, with a heavy class/wealth gradient.
• End-goal framing: this scene mostly aims at "survive to the next thing" — Aubrey de Grey's longevity escape velocity, and Bryan Johnson's "Don't Die" explicitly framed as a bridge to outlast the AI transition and reach radical life extension / (implicitly) substrate independence. See the two end-goals section at the bottom.

1. Flagship figures & programs

Bryan Johnson — Blueprint / "Don't Die" / Rejuvenation Olympics

• What he actually does: ex-Braintree/Venmo founder running "Project Blueprint" — a physician-team protocol tracking 100+ biomarkers, ~100 supplements/day, strict diet, exercise, sleep discipline, and experimental therapies; he claims ~$2M/yr spend. Famously did multigenerational plasma exchange with his father and son (later discontinued, "no benefit detected"). Discontinued rapamycin citing side effects (elevated glucose, infection susceptibility, impaired healing) and growth hormone (intracranial pressure, headaches). Variety, Frontiers/PMC rapamycin review
• Netflix doc: Don't Die: The Man Who Wants to Live Forever (dir. Chris Smith), released Jan 1, 2025. Wikipedia
• Rejuvenation Olympics: a public leaderboard (built with Dr. Oliver Zolman) ranking people by DunedinPACE "speed of aging" (an epigenetic clock; → longevity/research/measuring-aging.md). Johnson claims pace ~0.48–0.64 and #1 of ~5,600 competitors. rejuvenationolympics.com, Bryan Johnson, X
• "Don't Die" as movement/religion: in May 2025 Johnson reframed Don't Die as a decentralized "religion" ("the body is God"), with weekly small-group "Don't Die fam" meetings (modeled on AA), pitched as an ideology for the AI era — he argues solving aging takes decades, so humanity must align AI with human survival to last long enough. He stated an ambition to make it "the world's most influential ideology" within 18 months. MIT Technology Review
• Skeptic reception (substantial): Blueprint results are n=1 anecdote / case study — the weakest evidence tier — with no way to attribute effects to specific interventions; critics note others have matched his biological-age numbers far more cheaply; and the Rejuvenation Olympics has changed its rules/eligibility repeatedly without explanation (participants removed, an entire leaderboard once wiped), undermining its credibility as a "competition." ACSH, NOVOS critique
• See also longevity/research/great-debates.md §"Bryan Johnson: serious science or performance art?"

Andrew Huberman — Huberman Lab (the podcast-optimization sphere)

• What it is: Stanford neuroscientist running the top "protocols for everything" podcast (sleep, dopamine, light exposure, cold, focus). The format is mechanism-flavored lifestyle advice plus a large supplement/sponsor business.
• Commerce model: zero-cost-to-listener, monetized via sponsors — AG1 (he's been a brand partner since 2012), Momentous single-ingredient supplements, plus Eight Sleep, Whoop, LMNT, Function Health, etc. The protocols and the products are tightly coupled. Huberman Lab sponsors
• Skeptic reception: (1) A March 2024 New York Magazine exposé alleged he simultaneously deceived multiple romantic partners — a personal-conduct scandal that dented the "wellness guru" brand. (2) Scientists (e.g., Andrea Love) argue he often makes claims that sound scientific but lack evidence/plausibility; Rolling Stone had experts call his cannabis claims misleading/inaccurate. (3) He disclosed being on low-dose TRT (started at 45), prompting "hypocrisy" charges given he markets aging/optimization supplements. He nonetheless won "Best Wellness & Fitness Podcast" (2025 iHeartPodcast Awards). Wikipedia, Rolling Stone, Futurism (TRT)

Peter Attia — Outlive / "Medicine 3.0"

• What it is: physician, #1 NYT bestseller Outlive (2023, 2M+ copies). His "Medicine 3.0" frame = proactive, personalized, data-driven prevention vs. reactive "Medicine 2.0." Central distinction: healthspan (years free of disability/disease) over raw lifespan; emphasis on VO2max, zone-2 cardio, strength/grip, protein, the "marginal decade," and aggressive risk-factor management (ApoB, etc.). peterattiamd.com/outlive, Empirical Health on his 60 Minutes appearance
• Reception: the most evidence-respecting of the flagships; criticisms are milder — that Medicine 3.0 is expensive concierge medicine for the affluent, and that some recommendations (extensive early imaging, supplement use) outrun the evidence. His exercise/metabolic core aligns with the strong- evidence tier in longevity/research/what-actually-works.md.

Dave Asprey — Bulletproof (popularized "biohacking")

• Role: founder of Bulletproof (Bulletproof Coffee), credited by Merriam-Webster's "biohacker" definition with popularizing the consumer sense of "biohacking" (he didn't coin the word but mainstreamed it). Runs the annual Biohacking Conference. Wikipedia
• Reception: heavily on the grift end. No medical/nutrition training; the British Dietetic Association listed the Bulletproof diet as an example fad diet; in 2020 the FTC sent a warning letter over false COVID-19 prevention/treatment claims for his supplements. A 2025 Wired/Longreads piece on his conference (snake venom, urine therapy, MAHA-adjacent) captured the "do your own research vs. follow the science" tension. Longreads

Ben Greenfield — endurance/biohacking influencer

• Role: fitness/biohacking author and podcaster; founder of supplement brand KION. Pushes extensive stacks (NMN, glutathione, magnesium L-threonate, etc.) and, in 2025, leaned into GLP-1s and toward "simplicity" — publicly walking back many of his old extreme protocols. bengreenfieldlife.com 2025 biohacks
• Reception: archetype of the "maximalist stack" influencer; the recent pivot toward "the simple stuff works better" is itself a tacit admission about the prior maximalism.

2. The intervention canon (summary — depth is in longevity/ & peptides/)

This wing recycles a fairly fixed canon. Do not take the rankings below as primary — they compress longevity/research/interventions-ranked.md and what-actually-works.md:

The GLP-1 / Ozempic crossover (§3 below) is the single most important canon change of 2024–2026.

3. GLP-1s: the longevity-biohacking crossover story

GLP-1 receptor agonists (semaglutide/Ozempic, tirzepatide, retatrutide) jumped the fence from diabetes/obesity into the longevity-and-biohacking canon: - Cardiometabolic outcomes are real (SELECT trial: ~20% CV-event reduction; mortality signal — see longevity/research/interventions-ranked.md #9). - Aging-biomarker claims are emerging but softer: NIA/Yale work and a 2025 Cell Metabolism study report epigenetic-age and tissue-aging improvements (the latter in mice, partly independent of weight loss) — interesting, not established human anti-aging benefit. Spannr summary, PharmExec - Biohacker angle: grey-market GLP-1 sourcing (research-chem vials, compounded versions) overlaps directly with the peptide scene — pricing and suppliers are in peptides/list.md (semaglutide / tirzepatide / retatrutide / cagrilintide lines) and peptides/research/glp1-weight-loss/. - Honest take: genuinely the most evidence-backed new entry in the canon, but "first true anti-aging drug" framing is hype ahead of the human longevity data.

3b. Nootropics: the cognitive-enhancement sub-scene

Distinct from the longevity canon, nootropics ("smart drugs") are the cognitive-optimization wing — and they're the bridge between this consumer scene and the rationalist/quantified-self culture in 07-community-culture.md.

• The canon: the racetams (piracetam — coined the term "nootropic" via Romanian chemist Corneliu Giurgea in the 1970s — plus aniracetam, oxiracetam, phenylpiracetam, coluracetam); modafinil/armodafinil (wakefulness drug, the perennial favorite for sustained focus); the L-theanine + caffeine stack (the one combo with the most replicated evidence); cholinergics (alpha-GPC, citicoline); adaptogens; and a long grey-market tail (noopept, semax, etc.). Most have thin human efficacy evidence; modafinil and L-theanine+caffeine are the best-supported, racetams are largely unapproved in the US and sold as research chemicals. C3 · Gwern: Nootropics
• "Stack" culture: users assemble personal multi-ingredient stacks and iterate by feel — the same n=1 self-experimentation logic (and the same survivorship/placebo problems) as the supplement scene.
• The rigorous lineage: the standout is Gwern Branwen's long-running blinded, randomized, self-administered nootropics experiments (using placebo controls and statistical analysis of his own cognition) and the Slate Star Codex / Scott Alexander nootropics surveys — a rationalist-adjacent tradition of trying to actually test the stacks rather than vibe them. This is the cleanest example in all of consumer biohacking of self-experimentation done with real methodological discipline (still n=1, but blinded and analyzed). C3 · Gwern: Nootropics, Slate Star Codex nootropics survey
• Where they gather: r/Nootropics (large, broadly defined — it includes stimulants like modafinil and Adderall despite Giurgea's stricter "no usual side-effects" definition), r/StackAdvice, and vendor/community forums. C4 (community characterization) · NootropicGeek on r/Nootropics
• Honest take: mostly modest-to-no proven cognitive benefit beyond caffeine/sleep/exercise basics; the durable cultural contribution is the blinded self-experiment method (Gwern/SSC), not the compounds. It connects this consumer wing to LessWrong/rationalist culture (doc 07) more than to the hard-transhumanist end.

4. The quantified self: CGMs & wearables

The measurement layer that makes "optimization" feel scientific: - Oura (ring): sleep/HRV/temperature/readiness; reported >$500M revenue in 2024, targeting $1B in 2025. Added "Cumulative Stress." Athletech - Whoop (band): strain/recovery/sleep; 5.0 model (14-day battery); launched "Healthspan," a pace-of-aging metric tying daily behavior to longevity framing. the5krunner Whoop 5.0 review - Levels + Dexcom CGM: continuous glucose monitoring for non-diabetics — the on-ramp that turned "metabolic health" into a consumer category; Levels turns CGM data into a "Stability Score." go-health biohacking devices guide - Honest take: wearables are decent at relative trends (sleep regularity, training load) and weak at absolute accuracy; their main effect is behavioral (the act of measuring nudges behavior). They are the funnel into the rest of the commerce stack. For what the numbers mean see longevity/research/measuring-aging.md.

5. Community & commerce

• Market scale: vendor estimates for the broad "biohacking" market disagree by ~2× and should be read as a range, not a number — roughly $20B–$45B for 2025: GMInsights ~$28.2B (2025, from ~$24.5B in 2024), Astute Analytica ~$38.05B (→ ~$216.68B by 2035), and others (Mordor, Fortune, Precedence) scattered across that band with 10-year forecasts of ~$110B–$217B. Wearables + CGMs + metabolic monitoring are the declared growth drivers; longevity "discovery platforms" drew ~$2.65B in 2024. The same range is cited (consistently) in 01-grinder-diy-bodymod.md. GMInsights, Astute Analytica via GlobeNewswire, Mordor Intelligence (C4 — multiple market-research vendors disagreeing by ~2×; treat the precise figures as indicative, not gospel.)
• Online community: r/Biohackers (mainstream-optimization end; distinct from the harder-edge r/Biohacking grinder/DIY-bio threads — see 01-grinder-diy-bodymod.md), plus r/Nootropics (see §3b), r/Supplements, r/PeptideTherapy, r/Semaglutide. Culture is n=1 self-experimentation — personal protocols shared as if data, with all the attendant problems (no controls, placebo, survivorship, supplement-industry influence). (C4 — characterization from community knowledge; unsourced specific stats.)
• Conferences: Dave Asprey's Biohacking Conference (Austin, May 2025, "Living Beyond 180," 45+ speakers, 650+ attendees); RAADfest (RAADfest/Coalition for Radical Life Extension, DC); HOLOLIFE Summit (Tallinn ~2,000 attendees; Tokyo edition); Longevity Summit Canada. These range from serious-science-adjacent (RAADfest leans age-reversal science) to wellness-bazaar (snake venom, urine therapy on the Asprey floor). Longreads on Asprey 2025, conference roundup
• The grifter-to-serious spectrum (one axis, low → high rigor): Asprey / Greenfield (commerce-first, fad-prone) → Huberman (mechanism-flavored, sponsor-coupled, mixed) → Bryan Johnson (rigorous self-tracking but n=1 + performance + commerce) → Attia (most evidence- respecting, concierge-priced) → actual clinical longevity science (in longevity/ folder).

6. Honest take

• Real evidence vs. hype: The interventions with the strongest evidence in all of biohacking — exercise, sleep, metabolic health, not smoking — live in this wing, which is its genuine value. But these are free/cheap and boring; the scene's revenue comes from the weak-evidence layer (supplements, NAD+, most peptides, gadgets, $thousand blood panels). The branding inverts the evidence: the loudest claims attach to the thinnest data. (See what-actually-works.md Tiers 1→4.)
• Class/wealth dimension: this is optimization for the affluent — concierge medicine, $2M protocols, $300+ rings, recurring supplement spend, CGMs. The "longevity divide" (will life extension be a luxury good?) is a live critique; 68% of surveyed Americans expect benefits to go to the rich first. De Grey counters that mature rejuvenation would be too expensive to ration and effectively free — aspirational, unproven. longevity.technology / de Grey, PMC "Longevity Sticker Shock"
• Relation to the harder-edge scenes: this wing is the soft, consumer end of biohacking. It shares vocabulary and some compounds (peptides, GLP-1s, gene-therapy curiosity) with the grinders (01-grinder-diy-bodymod.md), DIY-bio (02-bay-bio-startups.md), and uploaders (04-wbe-uploading.md), but its methods are lifestyle + pharma, not implantation or emulation. The overlap is mostly ideological (transhumanism, "aging is a disease," radical life extension) rather than technical — see 07-community-culture.md.
• Conduct/credibility pattern: nearly every flagship has a credibility ding (Asprey FTC letter; Huberman exposé + supplement-science critiques; Johnson's rule-changing leaderboard + performance-art charge). The pattern is structural: media reach + supplement/product commerce creates incentives that pull away from evidence. Treat all flagship claims as marketing-adjacent until checked against the longevity/ docs.

Connections to the two end-goals

• Path to FiO / substrate independence: this wing is the "bridge" layer — its explicit logic (de Grey's longevity escape velocity; Bryan Johnson's "Don't Die") is stay alive and healthy long enough that the next, bigger thing arrives. Johnson makes the bridge explicit: solving aging takes decades, so the near-term task is surviving the AI transition (align AI with human survival) so you reach radical life extension — and, implicitly, whatever comes after (uploading/preservation). It does not itself build uploading tech; it buys time for 03-bci-neuralink.md / 04-wbe-uploading.md to mature. Brain preservation/cryonics (/workspace/cryonics/) is the harder version of the same "don't die before the tech arrives" bet.
• Path to biopunk-2037: weaker, mostly demand-side. This scene normalizes the idea that aging is engineerable and creates the affluent customer base and political tailwind (and the regulatory-softening "do your own research" culture) that regenerative/organ ventures (02-bay-bio-startups.md, /workspace/health/organ-sacs/) would sell into. It supplies consumers and capital and narrative, not bioengineered organs.

Open questions

• Does any flagship protocol beat "Tier 1 boring basics + GLP-1 if indicated"? No controlled evidence that Blueprint-style maximalism outperforms exercise/sleep/metabolic-health + selective drugs. (C5)
• GLP-1 longevity: will human studies confirm aging benefit independent of weight/cardiometabolic effects, or is it "just" excellent cardiometabolic medicine? (open; mouse data only for the weight- independent claim)
• Epigenetic-clock validity for ranking individuals: DunedinPACE etc. are research tools; are they robust enough to rank/score people (Rejuvenation Olympics, Whoop Healthspan)? → unresolved in measuring-aging.md. (C5)
• Market figures: the headline numbers come from market-research vendors that disagree by ~2× (GMInsights ~$28.2B vs Astute Analytica ~$38B for 2025, others $20–45B); they measure a fuzzy "biohacking" category differently. Best read as a ~$20–45B (2025) range, not a point estimate. (C4, flagged)
• "Don't Die" as ideology: will it persist as a real movement or fade as Johnson-branded content? Too early; the "religion" framing is <1 year old (May 2025). (C5)

Cross-links

• Science/evidence depth: /workspace/health/longevity/ — esp. research/interventions-ranked.md, what-actually-works.md, measuring-aging.md, great-debates.md, funding-landscape.md
• Compounds/grey-market: /workspace/health/peptides/ (GLP-1s, NAD+, BPC-157, epithalon, MOTS-c, SS-31…)
• Grinder/DIY end of biohacking: 01-grinder-diy-bodymod.md
• Bay bio / regenerative / organ ventures: 02-bay-bio-startups.md, /workspace/health/organ-sacs/
• The "don't die before the tech arrives" hard version: /workspace/cryonics/, 04-wbe-uploading.md
• Ideology/community/transhumanism overlap: 07-community-culture.md